MedTrace Logo

Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes

NCT00106808 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1440

Last updated 2010-09-14

No results posted yet for this study

Summary

The purpose of this study is to compare Muraglitazar and Pioglitazone in patients with Type 2 Diabetes. Both the safety and blood sugar lowering effects of these treatments will be studied.

Conditions

Interventions

DRUG

Muraglitazar

DRUG

Pioglitazone

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2006-08-31
Completion
2006-08-31

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Canada
  • Chile
  • India
  • Mexico
  • Peru
  • Philippines
  • Russia
  • Taiwan
  • Thailand
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00106808 on ClinicalTrials.gov